Vancomycin-resistant Staphylococcus aureus: A real and present danger?

被引:27
作者
Hamilton-Miller, JM [1 ]
机构
[1] UCL Royal Free & Univ Coll, Sch Med, Dept Med Microbiol, London NW3 2PF, England
关键词
Staphylococcus aureus; MRSA; vancomycin-intermediate; S; aureus; antibiotic resistance;
D O I
10.1007/s15010-002-2160-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The glycopeptide antibiotics, vancomycin and teicoplanin, are the mainstay of therapy for infections involving strains of Stapylococcus aureus that are resistant to methicillin and gentamicin. During the last 5 years, clinical isolates of S. aureus showing reduced susceptibility to glycopeptides have been reported from many countries around the world, often associated with prolonged glycopeptide therapy. Detection and monitoring of such strains has been hindered by the fact that vancomycin (or glycopeptide)-intermediate S. aureus (VISA) isolates may be missed on conventional disk sensitivity tests. Effective control measures are required to prevent the increasing occurrence and spread of such strains in both the hospital and community settings. An important aspect of control is promoting the judicious use of glycopeptides. The recent introduction of the alternative antibiotics quinupristin/dalfopristin and linezolid, which are active against S. aureus strains resistant to many other classes of agent, should facilitate this process.
引用
收藏
页码:118 / 124
页数:7
相关论文
共 83 条
  • [1] Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations
    Akins, RL
    Rybak, MJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) : 454 - 459
  • [2] Antimicrobial resistance in Gram-positive pathogens isolated in the UK between October 1996 and January 1997
    Andrews, J
    Ashby, J
    Jevons, G
    Lines, N
    Wise, R
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (05) : 689 - 698
  • [3] Linezolid, a novel oxazolidinone antibiotic: Assessment of monoamine oxidase inhibition using presser response to oral tyramine
    Antal, EJ
    Hendershot, PE
    Batts, DH
    Sheu, WP
    Hopkins, NK
    Donaldson, KM
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (05) : 552 - 562
  • [4] Arciola CR, 1999, MICROBIOLOGICA, V22, P337
  • [5] Ayliffe GAJ, 1998, J HOSP INFECT, V39, P253, DOI 10.1016/S0195-6701(98)90293-6
  • [6] Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates
    Boyle-Vavra, S
    Berke, SK
    Lee, JC
    Daum, RS
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) : 272 - 277
  • [7] Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus:: Evidence of resistance to vancomycin
    Burnie, J
    Matthews, R
    Jiman-Fatami, A
    Gottardello, P
    Hodgetts, S
    D'arcy, S
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 31 (03) : 684 - 689
  • [8] Linezolid
    Clemett, D
    Markham, A
    [J]. DRUGS, 2000, 59 (04) : 815 - 827
  • [9] Quinupristin-dalfopristin: An overview
    Delgado, G
    Neuhauser, MM
    Bearden, DT
    Danziger, LH
    [J]. PHARMACOTHERAPY, 2000, 20 (12): : 1469 - 1485
  • [10] INVITRO ACTIVITY OF 6 ANTIBIOTICS AGAINST MULTIRESISTANT STAPHYLOCOCCI AND OTHER GRAM-POSITIVE COCCI
    DIXSON, S
    BRUMFITT, W
    HAMILTONMILLER, JMT
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1985, 4 (01) : 19 - 23